Novartis vaccines and Diagnostics
Novartis Vaccines
22
0
22
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+20 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (20)
Showing 10 of 20 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Melissa Stockwell, MD MPH
Columbia University
Shared therapeutic areas:
Veryl Hodges, DO
Clopton Clinic
Shared therapeutic areas:
Shaukat A. Shah, MD
St. Joseph's Medical Associates, Stockton, CA 95204
Shared therapeutic areas:
Keith S. Reisinger, MD, MPH
Primary Physicians Research, Inc
Shared therapeutic areas:
Giuseppe D'Ignazio, MD
Source Unique Clinic
Shared therapeutic areas:
Lawrence P. Schwartz, MD
HCCA Clinical Research Solutions, New York, NY 10016
Shared therapeutic areas:
Terry L Poling, MD
Heartland Research Associates, LLC, Wichita, KS 67207
Shared therapeutic areas:
Michael Warren, MD
Research Across America at Oyster Point Family Health Center
Shared therapeutic areas:
Douglas W Mapel, MD
Clinical Trial Connection, Flagstaff, AZ 86001
Shared therapeutic areas:
Karl V Sitz, MD
Little Rock Allergy & Asthma Clinical Research Center, Little Rock, AR 72205
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (22)
Showing 20 of 22 trials
Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above
Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects
Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia
Study to Identify Factors Influencing Access of Pregnant Women and Their Infants to Local Healthcare Systems
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.
Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above
Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above
Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28